Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Cymraeg
Cymraeg
Search
Menu
Home
Accessing medicines
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Sodium valproate information hub
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Our committees
Who we are
What we do
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Accessing medicines
›
One Wales Medicines process
›
One Wales medicine assessment documents
›
OW30 documents
OW30 documents
20/06/2025
OWMAG decision rationale trametinib OW30
20/06/2025
Trametinib (Mekinist) ESR redacted for website OW30
20/06/2025
trametinib (Mekinist) - equality and health impact assessment final OW30
20/06/2025
Recommendation and start stop criteria Trametinib for LGSOC OW30
20/06/2025
Prisma tramatinib
20/06/2025
Table 5. Estimated net annual cost for trametinib versus NHS Wales standard of care
20/06/2025
Table 4: Summary of cost-comparison results
20/06/2025
Table 3. Costs of trametinib and standard-of-care per patient for first year of treatment
20/06/2025
Table 2. Standard of care (SOC) comparator treatments in NHS Wales
20/06/2025
Table 1. Primary and secondary outcomes of Study GOG 281/LOGS (6)
Follow AWTTC:
